Heritage Pharmaceuticals, an East Brunswick, NJ-based specialty generic pharmaceutical company, has appointed William Marth as president and chief executive officer, North America and Europe, of the company’s parent, Heritage Pharma Holdings. Mr. Marth also will be appointed as a member of the company’s board of directors and a member of the board of directors for two of the company’s affiliates, Marcan Pharmaceuticals (Canada) and Emcure Pharma UK Limited (Europe).

Mr. Marth previously served as the president and chief executive officer for AMRI, a global contract research and manufacturing organization, until January 2018. From 1999 until 2012, Mr. Marth played a key role in establishing Teva Pharmaceuticals as a leading specialty pharmaceutical company in increasingly important positions, and serving as the president and chief executive officer of Teva Americas until his retirement in 2012, remaining as a senior advisor to Teva until December 2013.

Heritage also named John Denman as the president of Heritage Pharmaceuticals Inc. Mr. Denman is an experienced leader with deep expertise in the commercial side of generic pharmaceuticals, including customer related agreements, programs, and third-party payors, product portfolio selection, product launch, and product life cycle management.

Mr. Denman joins Heritage from Renaissance SSA LLC, a proprietary drug product manufacturer based in Newtown, PA, where he served as the president and chief executive officer in charge of the sterile products division. Previously, in his more than 16 years in the generic pharmaceutical industry, Mr. Denman worked for Renaissance Pharma Inc., Teva Pharmaceuticals, and Sandoz Inc., where he held a variety of leadership roles, with responsibility for commercial operations, sales and marketing, and global customer service.

“We are very pleased that Bill Marth and John Denman have decided to join our team,” said
Marvin Samson, chairman of the Heritage board of directors. “Bill is a recognized leader in the pharmaceutical industry who possesses invaluable expertise in formulating and executing strategic initiatives that have transformed pharmaceutical businesses. John is another great addition to the leadership team, having worked closely with Bill during his tenure with Teva.”